Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

5th Annual "Cancer Immunotherapy: A Long- Awaited Reality" Conference Taking Place March 26, 2015 in New York City
  • USA - English


News provided by

Kureczka/Martin Associates

Feb 25, 2015, 10:00 ET

Share this article

Share toX

Share this article

Share toX

New York, NY (PRWEB) February 25, 2015 -- The 5th Annual “Cancer Immunotherapy: A Long-Awaited Reality” conference will take place on March 26, 2014 at the New York Academy of Medicine in New York City. This single-day conference brings together visionary researchers and clinicians, business leaders, key investors, and other stakeholders to discuss in-depth science, business issues, and investment opportunities in the field of cancer immunotherapy. The conference format is designed to foster networking, knowledge sharing and learning in an interactive environment.

Keynote speakers and panels will feature discussions by noted scientific and clinical thought leaders, industry executives, and institutional investors on

• The future of cancer immunotherapy in the era of PD1/PDL1 inhibitors
• High-Priority Immunotherapy Agents in Development
• Checkpoint Modulators- Next Generation
• Unleashing the power of the immune system through combination therapy
• Combination themes: What combination will convert non-responders to responders? What combination will improve response among responders?
• Unlocking the immune response through innate immune modulation
• CAR/TCR engineered T cells: What solid tumors will be treated effectively with CAR/TCR engineered T cells? What role does the combination with CPIs have with CAR/TCR engineering T cells?
• We have a Model A; Can We Build a Ferrari?
• Immunotherapies in the Adjuvant Setting
• Immune augmentation + tumor destruction: in-situ vaccine?
• Turning a tumor into a vaccine factory: In situ vaccination for low-grade lymphoma

Key speakers for 2015 include:
• Renier J. Brentjen, MD, Ph.D.- Director, Cellular Therapeutics, Memorial Sloan Kettering Cancer Institute
• Joshua Brody, MD- Director, Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai
• Martin "Mac"Cheever, MD--Principal Investigator, Cancer Immunotherapy Trials Network, Member, Fred Hutchinson Cancer Research Center, Professor of Medicine/Oncology, University of Washington
• James Gulley, MD, Ph.D.--Chief, Genitourinary Malignancies Branch Director, Medical Oncology Service, Center for Cancer Research, NCI, NIH
• Michael Kalos, Ph.D.--Chief Scientific Officer, Cancer Immunobiology Lilly Research Laboratories, Eli Lilly and Company
• Holbrook Kohrt, MD, Ph.D.--Assistant Professor, Stanford University School of Medicine
• Reiner Laus, MD—CEO of Annias Immunotherapeutics, Former President & CEO, Bavarian Nordic Immunotheraputics
• Ignacio Melero, MD, Ph.D.--CIMA and Clinica Universidad de Navarra
• George E. Peoples, MD, FACS--COL (ret), MC, USA, Founder and CEO, Cancer Insight, LLC, Director, Cancer Vaccine Development Program, Professor, Surgery, Uniformed Services University, Professor (adjunct), Surgical Oncology, MD Anderson Cancer Center
• Robert Pierce, MD--Chief Medical Officer of OncoSec Medical Inc.
• Neil H. Segal, MD, PhD--Deputy Director, Immunotherapeutics Group, Memorial Sloan Kettering
• Robert Sikorski, M.D., Ph.D.-- Vice President, Global Clinical Development, Five Prime Therapeutics
• Robert Stein, MD, Ph.D, Chief Scientific Officer of Agenus Inc.
• Paul Tumeh, MD—Assistant Professor, Department of Medicine, Dermatology Member, JCCC Tumor Immunology Program Area, UCLA

“This conference provides an excellent opportunity to increase your knowledge of the advances and developments in Immuno-oncology,” said Janet L. Dally, founder and managing director of MaidStone Life Sciences, LLC. “The intimate venue also allows attendees to build relationships with experts from noted research institutions and industries.”

MaidStone Life Sciences LLC is the host for the event, with support from Kureczka/Martin Associates. The meeting is also sponsored by Five Prime Therapeutics, Inc. and Great Minds Software.

For more information about the event, please visit the event website at http://www.maidstonels.com/conference.html.

For information regarding conference registration, sponsorship opportunities, and one of the limited company presentation slots available please contact Janet Dally at 609-466-0466 or janetdally at maidstonelifesci.com. Members of the media wishing to attend the event should contact Joan Kureczka, Joan at Kureczka-Martin.com or call 415-821-2413.

About MaidStone Life Sciences, LLC
MSLS is a strategic advisor and partner, providing a full range of services to help our clients increase visibility, unlock stakeholder value and access resources to grow their business. We are a boutique management, investor relations and strategy consulting firm focusing on both public and private companies in the life sciences industry. We have an extensive network of venture capitalists, institutional investors, high net worth individuals, and other sources of capital.

###

Joan Kureczka, Kureczka/Martin Associates, +1 (415) 821-2413, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.